Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Cubist Pharmaceuticals, Inc. (CBST - Analyst Report) recently inked a deal with Japanese company Astellas Pharma Inc. (ALPMY) to acquire the remaining rights of ceftolozane from the latter. Ceftolozane is the key component of Cubist Pharma's antibiotic candidate CXA-201 (ceftolozane/tazobactam).  

Following the new agreement, Cubist Pharma gained the rights to develop and market CXA-201 in certain Asia-Pacific and Middle East countries. Cubist Pharma now has global rights pertaining to CXA-201.

As per the terms of the new agreement, Cubist Pharma will make an upfront payment of $25 million to Astellas Pharma. Cubist Pharma intends to make the payment through its available cash balance.

CXA-201 was added to Cubist Pharma’s pipeline following its acquisition of Calixa Therapeutics, Inc. in 2009. CXA-201 is one of the most interesting candidates in Cubist Pharma’s pipeline. The candidate is undergoing phase III studies in the complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) indications.

Cubist Pharma expects to report top-line data from the studies in the second half of 2013. The company intends to seek US approval for both indications (cUTI and cIAI) within approximately 6 months of reporting top-line data from both the phase III studies.

Cubist Pharma also intends to evaluate CXA-201 in a phase III study for treating patients suffering from nosocomial pneumonia. The study is expected to commence in mid-2013.

The US Food and Drug Administration (FDA) has already provided QIDP (qualified infectious disease product) status to CXA-201 for all the above indications. With the FDA granting CXA-201 QIDP status for the above indications, the antibiotic qualifies for multiple benefits including a 5-year extension of Hatch-Waxman exclusivity (on approval) and priority review.

Cubist Pharma, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Biopharma stocks such as Array Biopharma (ARRY - Snapshot Report) and Kythera Biopharmaceuticals, Inc. (KYTH - Snapshot Report) are comparatively well placed and carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%